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Abstract
The epithelial and epidermal innate cytokines IL-25, IL-33, and thymic stromal lymphopoietin 
(TSLP) play pivotal roles in the initiation of allergic inflammation in asthma and atopic dermatitis. 
However, the mechanism by which the expression of these innate cytokines is regulated remains 
unclear. Intelectin (ITLN) is expressed in airway epithelial cells and promotes allergic airway 
inflammation. We hypothesized that ITLN is required for allergen-induced IL-25, IL-33 and TSLP 
expression. In two asthma models, Itln knockdown reduced allergen-induced increases in Il-25, 
Il-33, and Tslp and development of type 2 response, eosinophilic inflammation, mucus 
overproduction, and airway hyperresponsiveness. Itln knockdown also inhibited house dust mite 
(HDM)-induced early upregulation of Il-25, Il-33, and Tslp in a model solely inducing airway 
sensitization. Using human airway epithelial cells, we demonstrated that HDM-induced increases 
in ITLN led to phosphorylation of EGFR and ERK which were required for induction of IL-25, 
IL-33, and TSLP expression. In two atopic dermatitis models, Itln knockdown suppressed 
expression of Il-33, Tslp and Th2 cytokines and eosinophilic inflammation. In humans, ITLN1 
expression was significantly increased in asthmatic airways and in lesional skin of atopic 
dermatitis. We conclude that intelectin contributes to allergen-induced Il-25, Il-33 and Tslp 
expression in asthma and atopic dermatitis.
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INTRODUCTION
Asthma is an increasingly common disease which is characterized by allergic airway 
inflammation, airway hyperresponsiveness, mucus overproduction and peribronchial 
fibrosis 1. Atopic dermatitis (AD) is a chronic inflammatory skin disease with a worldwide 
prevalence of 1–20% 2, and is frequently associated with asthma 3. The type 2 immune 
response plays pivotal roles in the pathogenesis of both asthma and the acute phase of AD. 
Type 2 cytokines such as IL-4, IL-5, and IL-13 are expressed in asthmatic airways and in 
acute eczematous lesions 4–6.
The epithelial- and epidermal-derived cytokines IL-25, IL-33 and TSLP are upregulated 
during innate immune responses to allergen in asthma and AD and prime type 2 immune 
responses by acting on innate and adaptive immune cells 7, 8. TSLP activates dendritic cells 9 
and also directly promotes naive CD4+ T cells to into type 2 helper T cells (Th2 cells) 10. 
IL-25, IL-33, and TSLP can stimulate group 2 innate lymphoid cells (ILC2) to release type 2 
cytokines 11–14. IL-25 15–18, IL-33 19, and TSLP 10 have each been reported to be both 
necessary and sufficient for type 2 production, eosinophilic airway inflammation, mucous 
metaplasia, and airway hyperresponsiveness in mouse asthma models. Overexpression of 
TSLP in skin keratinocytes is sufficient to induce a type 2 response and atopic dermatitis-
like phenotype in mice 20. In subjects with asthma, bronchial epithelial expression of 
TSLP 21, IL-25 22, 23, and IL-33 24 have been reported to be upregulated. In the skin of with 
atopic dermatitis, the expression of IL-33 and TSLP are increased in epidermal 
keratinocytes 20, 25. However, the mechanism by which the expression of IL-25, IL-33 and 
TSLP is regulated in bronchial epithelial cell and epidermal keratinocytes remains unknown. 
Identifying the epithelial and epidermal-derived mediator that regulates the expression of 
these cytokines is essential for understanding the molecular mechanism of initiation of 
asthma and atopic dermatitis.
Lectins are a group of molecules that play important roles in innate immune response to 
pathogens 26–28. Human intelectin-1 (ITLN1) is a soluble lectin that recognizes 
galactofuranose in carbohydrate chains of the bacterial cell wall 29. ITLN1 has been shown 
to bind Mycobacterium bovis bacillus Calmette–Guerin (BCG) 30, Streptococcus 
pneumoniae 31, V. cholerae and other enteric bacterial pathogen 32. Intelectin expression is 
increased rapidly after gastrointestinal nematode parasite infection in mice and sheep 33–35. 
These data suggest that intelectin may play a role in innate immune response in pathogen 
defense. ITLN1 is upregulated in bronchial epithelial brushings and induced sputum of 
subjects with asthma 36–38. It has been reported that a single-nucleotide polymorphism in 
ITLN1 is associated with increased asthma risk 37. Mouse intelectin (Itln) expression is also 
increased in ovalbumin (OVA) allergic mice and IL-13-overexpressing mice 36, 39. We have 
previously reported that Itln contributes to airway eosinophilic inflammation in OVA allergic 
mice 40. Because intelectin is implicated in the innate immune response, we hypothesize that 
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intelectin is upregulated at early stage after allergen sensitization of the airway and is 
required for the expression of IL-25, IL-33, and TSLP.
To test our hypothesis, we developed a transgenic mouse in which Itln expression was 
conditionally suppressed by short hairpin RNA (shRNA) against Itln. We investigated the 
role of Itln in the pathogenesis of asthma models induced by OVA or house dust mite 
(HDM), and in atopic dermatitis models induced by vitamin D3 analogue calcipotriol 
(MC903) or HDM. We further examined the role of Itln in the HDM-induced Il-25, Il-33, 
and Tslp expression at the sensitization phase of asthma. Moreover, we examined the 
expression of ITLN1 in subjects with asthma and atopic dermatitis.
RESULTS
Itln knockdown mice are protected from allergen-induced airway hyperresponsiveness, 
eosinophilic inflammation and mucus metaplasia in two allergic asthma models
Itln knockdown (KD) mice and control mice on the same background (C57BL/6) were 
sensitized and challenged by intranasal administration of OVA or saline. We measured the 
mRNA levels of Itln1 (the only Itln gene in C57BL/6 mice 34) by quantitative PCR. Itln1 
expression was significantly increased in the lung of OVA-challenged WT mice compared to 
saline-challenged WT mice. However, the increase of Itln1 expression was markedly 
suppressed, reduced by 58.8% in protein level, in the lung tissue in OVA-challenged ITLN 
KD mice compared to WT mice (Supplementary Figure S1 online).
We investigated the role of Itln in AHR, airway inflammation and mucus overproduction. 
Airway response to acetylcholine was the same in saline-challenged WT and Itln KD mice. 
However, OVA-challenged Itln KD mice were significantly protected from AHR when 
compared with WT mice (Figure 1a). The numbers of total cells and eosinophils in 
bronchoalveolar lavage fluid (BALF) and the numbers of inflammatory cells around the 
conducting airways assessed by H&E staining were significantly lower (>50% reduction) in 
OVA-challenged Itln KD mice when with WT mice (Figure 1b–d). The numbers of periodic 
acid-schiff (PAS)-staining-positive, MUC5AC-staining-positive cells and the levels of 
Muc5ac transcripts were markedly reduced in OVA-challenged Itln KD mice compared with 
WT mice (Figure 1e–h). Serum levels of OVA-specific IgE were significantly decreased in 
OVA-challenged Itln KD mice when compared to WT mice (Figure 1i). Our data indicated 
that Itln plays a key role in the development of AHR, airway inflammation, mucus 
overproduction and allergic response in a murine asthma model induced by OVA.
We also investigated the role of Itln in the pathogenesis of asthma using the house dust mite 
(HDM) asthma model, since this allergen is more relevant to human asthma. Itln1 transcript 
level increased in the lung of HDM-challenged WT mice but was significantly suppressed in 
HDM-challenged Itln KD mice (Supplementary Figure S2a). Similar to our findings in OVA 
asthma model, HDM-challenged Itln KD mice were protected from AHR when compared 
with WT mice (Supplementary Figure S2b). The numbers of total cells and eosinophils in 
BALF, inflammatory cells around conducting airways, and mucus-containing cells were 
significantly less in HDM-challenged Itln KD mice when compared with WT mice 
(Supplementary Figure S2c–e). Total serum IgE levels were decreased in HDM-challenged 
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Itln KD mice when compared with WT mice (Supplementary Figure S2f). These data that 
Itln plays a key role in the development of AHR, airway inflammation, mucus 
overproduction and allergic response in the HDM asthma model.
Itln is involved in the development of Th2 immune responses in allergic asthma models
We next investigated whether Itln is required for the development of Th2 immune response 
in mouse OVA asthma model. We analyzed the expression of the Th2 cytokines Il-4, Il-5, 
and Il-13 in mouse lung by quantitative PCR and ELISA. OVA challenge induced the 
expression of Il-4, Il-5, and Il-13 in lung tissue and BALF of WT mice. However, the 
increase of these cytokines was significantly suppressed in OVA-challenged Itln KD mice 
(Figure 2a–f). We also evaluated the immune response by intracellular cytokine staining of 
the T cell subsets isolated from lung tissue and mediastinal lymph node. We found that 
percentages of Th2 cells (IL-4+CD4+) were increased in lung tissue and draining lymph 
node of OVA-challenged WT mice, but significantly decreased in OVA-challenged Itln KD 
mice (Figure 2g,h). Our data indicate that Itln contributes to the development of Th2 
immune response in asthma.
We also determined the expression of Il-4, Il-5, and Il-13 in HDM sensitized and challenged 
mouse lung by quantitative PCR. We found that the expression of these cytokines was 
increased in lung tissue of HDM-challenged WT mice, but significantly suppressed in 
HDM-challenged Itln KD mice (Supplementary Figure S3a–c).
Itln contributes to the upregulation of the airway epithelial cytokines IL-25, IL-33, and TSLP 
after exposure to allergen
Il-25, Il-33 and Tslp are key players in the innate immune response of epithelial to allergens 
and promote Th2 immune responses in asthma 7. OVA (Figure 2i–k) and HDM 
(Supplementary Figure S3d–i) challenge each increased lung Il-25, Il-33 and Tslp protein 
levels in WT mice, but these increases were significantly suppressed in KD mice. Our data 
indicate that Itln is required, at least in part, for upregulation of Il-33 and Tslp in the airway 
epithelium after allergen sensitization and challenge. cytokines were still induced in OVA 
and HDM-challenged Itln KD mice compared control Itln KD mice, which could be 
attributed to the incomplete knockdown of Itln expression.
To test our hypothesis that Itln may participate in airway innate immune responses to 
allergen by regulating the expression of Il-25, Il-33 and Tslp, we used a model inducing 
sensitization without obvious airway inflammation to examine the kinetics of Itln1, Il-25, 
Il-33 and Tslp expression at the allergen sensitization phase 41. In this model, there were 
only 3 consecutive daily intranasal challenges with HDM. We found that HDM induced the 
expression of Itln1, Il-25, Il-33 and Tslp at 2 and 6h after the last HDM exposure in the lung 
of WT mice (Figure 3a–d). However, HDM-induced upregulation of Itln1, Il-25, Il-33 and 
Tslp were markedly suppressed in ITLN KD mice (Figure 3e–h). Our data indicate that Itln 
is involved in the upregulation of Il-25, Il-33 and Tslp in the sensitization phase of asthma.
We next sought to establish an in vitro system to confirm and extend our in vivo finding that 
airway ITLN1 plays a key role in IL-25, IL-33 and TSLP expression after HDM exposure. 
We examined the expression of these cytokines in BEAS-2B human bronchial epithelial 
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cells after exposure to HDM for 0, 2, 6, 24 h. HDM induced IL-25, IL-33 and TSLP 
expression in BEAS-2B cells at 2 and 6h. However, HDM-induced increases in these 
cytokines were suppressed when ITLN1 expression was silenced by RNA interference 
(Figure 4a–h, Supplementary Figure S4a–c). Pretreatment of BEAS-2B cells with galactose, 
which binds to ITLN1 and can be used as an inhibitor of ITLN1 29, also inhibited HDM-
induced IL-25, IL-33, and TSLP mRNA expression (Supplementary Figure S4d–f). Our data 
indicate that ITLN1 is necessary for allergen-induced IL-25, IL-33, and TSLP expression in 
human airway epithelial cells.
Since the activation of epidermal growth factor receptor (EGFR) and extracelluar signal-
regulated kinases (ERK) has been implicated in the expression of IL-33 and TSLP 
expression in keratinocytes 42, 43, we examined whether the ERK cascade is involved in 
HDM-induced IL-25, IL-33 and TSLP expression in BEAS-2B cells. We found that the 
EGFR inhibitors AG1478 and PD153035 and the ERK kinase inhibitor U0126 each blocked 
HDM-induced IL-25, IL-33, and TSLP expression in BEAS-2B cells (Supplementary Figure 
S5a–i). Furthermore, HDM stimulation increased EGFR and ERK phosphorylation at 2h and 
4h, respectively, and ITLN1 shRNA transfection inhibited HDM-induced EGFR and ERK 
phosphorylation (Figure 4i–k). These data indicate that the activation of EGFR and ERK 
mediates HDM-induced IL-25, IL-33, and TSLP expression, and that ITLN1 expression 
contributes to HDM-induced EGFR and ERK activation in human bronchial epithelial cells.
Itln contributes to IL-33 and TSLP expression and Th2 inflammation in two atopic 
dermatitis models
Atopic dermatitis is another allergic disease characterized by Th2 inflammation. We 
investigated the role of Itln in a murine model of atopic dermatitis induced by topical 
application of the vitamin D3 analogue calcipotriol (MC903) to the ear 44, 45. Itln1 transcript 
levels were increased in the lesional skin exposed to MC903 for 9 days in WT mice, but 
markedly reduced in Itln KD mice (Figure 5d). Immunohistochemistry showed many Itln-
positive keratinocytes in the skin exposed to MC-903 in WT mice (Figure 5e). MC903-
treated WT mice had red, scaly skin with markedly increased ear thickness and proliferation 
of keratinocytes, but these pathological changes were significantly attenuated in MC903-
treated Itln KD mice (Figure 5a,e). Dermal infiltration of eosinophils was abundant in 
MC903-treated WT mice but reduced in Itln KD mice (Figure 5b). Moreover, serum IgE 
level was increased in MC903-exposed WT mice but significantly reduced in Itln KD mice 
(Figure 5c). Our data indicate that Itln contributes to MC903-induced allergic skin 
inflammation.
Furthermore, we examined the expression of Th2 cytokines in ear tissue by quantitative 
PCR. MC903 induced the expression of Il-4, Il-5, and Il-13 in ear tissues WT mice. 
However, increases of these cytokines were suppressed in MC903-exposed Itln KD mice 
(Supplementary Figure S6a–c). Tslp has been reported to be expressed in keratinocytes and 
play a pivotal role in MC903-induced atopic dermatitis 45. We found the level of Tslp and 
Il-33 transcripts but not Il-25 transcript was markedly increased in the lesional ear of 
MC903-exposed WT mice. However, the upregulation of Tslp and Il-33 were suppressed in 
Itln KD mice (Supplementary Figure S6d–e). Our data indicate that Itln is required, at least 
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in part, for the expression of Tslp, Il-33 and Th2 cytokines in MC903-induced atopic 
dermatitis. Tslp and Il-33 were still induced in MC903-exposed Itln KD mice compared 
with control Itln KD mice, which could be attributed to the incomplete knockdown of Itln 
expression.
We also used another atopic dermatitis model induced by HDM to investigate the role of Itln 
in allergic skin inflammation 46. Itln expression was increased in the ear skin of WT mice 
exposed to HDM for 5 weeks. However, the upregulation of Itln1 was suppressed in Itln KD 
mice. Ear thickness, eosinophil infiltration and serum IgE level were increased in HDM-
exposed WT mice but reduced in HDM-exposed Itln KD mice (Supplementary Figure S7a–
d). Moreover, Tslp, Il-33 and Th2 cytokine expression was significantly increased in the ear 
of HDM-exposed WT mice but markedly suppressed in Itln KD mice (Supplementary 
Figure S7e–j).
ITLN1 expression is increased in the airway of subjects with asthma and in the lesional 
skin of atopic dermatitis
We recruited 23 healthy controls and 48 subjects with asthma. Subject characteristics are 
summarized in Supplementary Table S1. Subjects with asthma had lower FEV1 and 
methacholine PD20 and higher serum IgE levels and blood eosinophil numbers than healthy 
control subjects.
We examined ITLN1 transcript levels in bronchial brushings from healthy controls and 
subjects with asthma by quantitative PCR. ITLN1 transcript levels were markedly increased 
in subjects with asthma when compared with healthy controls (Figure 6a). ITLN1 
immunostaining in bronchial biopsy samples revealed that ITLN1-positive cells were mainly 
airway mucous cells and submucosal gland cells (Figure 6b).
We investigated whether ITLN1 expression is associated with IL-25 expression in epithelial 
brushings. We previously reported that the transcript levels of IL-25, but not IL-33 or TSLP, 
were increased in bronchial brushings from subjects with asthma compared to healthy 
controls 47. We found epithelial ITLN1 transcript levels were correlated with IL-25 levels 
when all subjects were included (ρ=0.378, p=0.001) (Figure 6c). However, this correlation 
was weak when only subjects with asthma were included (ρ=0.13, p=0.379).
Furthermore, epithelial ITLN1 transcript levels were significantly correlated with the levels 
of eosinophils in induced sputum when all subjects were included (ρ=0.696, p<0.0001), and 
this correlation remained significant when only subjects with asthma were included 
(ρ=0.622, p<0.0001) (Figure 6d). The correlations between epithelial ITLN1 transcript 
levels and FEV1, methacholine PD20, and eosinophils in bronchial biopsies were also 
significant when all subjects were included, but these correlations were weak when only 
subjects with asthma were included (Supplementary Figure S8).
Since ITLN1 is secreted protein, we measured ITLN1 protein levels in induced sputum and 
plasma. We found that plasma and sputum ITLN1 protein levels were significantly increased 
in subjects with asthma when compared with healthy controls (Figure 6e,g). Sputum ITLN1 
protein levels were significantly correlated with the levels of eosinophils in induced sputum 
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when all subjects were included (ρ=0.85, p<0.0001). Importantly, this correlation remained 
significant when only subjects with asthma were included (ρ=0.73, p<0.0001) (Figure 6f). 
This indicates that sputum ITLN1 may be a useful non-invasive biomarker for airway 
eosinophilia. Sputum and plasma ITLN1 protein levels were also significantly correlated 
with FEV1, methacholine PD20, and eosinophils in bronchial biopsies, and plasma ITLN1 
protein levels were correlated with eosinophils in induced sputum when all subjects were 
included (Supplementary Figures S9 and S10), but these correlations were weak when only 
subjects with asthma were included.
We also examined the expression of ITLN1 protein in skin biopsies of subjects with AD and 
control subjects by immunohistochemistry. ITLN1 was expressed in the keratinocytes of 
lesional skin of subjects with chronic AD. However, there were few if any ITLN1-positive 
cells in control subjects (Figure 7).
DISCUSSION
In the present study, we demonstrated that Itln, a molecule expressed in airway epithelial 
cells and skin keratinocytes, plays a key role in the epithelial and epidermal expression of 
Il-25, Il-33, Tslp and the type 2 immune response in murine models of allergic asthma and 
atopic dermatitis, respectively. We found that Itln1 is upregulated rapidly in the airway after 
allergen exposure and contributes to allergen-induced Il-25, Il-33 and Tslp expression at the 
sensitization phase of asthma. We also demonstrated that ITLN1 expression is increased in 
the airway of subjects with asthma and in lesional skin of subjects with atopic dermatitis.
Human ITLN1 is a soluble lectin that recognizes galactofuranose in carbohydrate chains of 
the bacterial cell wall 29. Intelectin expression is increased rapidly after gastrointestinal 
nematode parasite infection in mice and sheep 33–35. Human ITLN1 been shown to bind 
Mycobacterium bovis bacillus Calmette–Guerin 30 and Streptococcus pneumoniae 31. In a 
recent study, Hatzios and colleagues found that intelectin bound to V. cholerae and other 
enteric bacterial pathogen. Intelectin was degraded by V. cholerae protease, which may 
contribute to the infection of V. cholera These reports suggest that intelectin plays a role in 
the innate immune response of pathogen defense.
We have previously reported that airway eosinophilic inflammation and mucus production 
were inhibited after airway transfection with Itln shRNA in an OVA model 40. In the present 
study, we generated transgenic Itln knockdown mice and that AHR, airway eosinophilic 
inflammation, mucus overproduction, and type 2 immune response were significantly 
suppressed in Itln KD mice not only in the OVA asthma model but also in an HDM asthma 
model. With Itln KD mice, we were able to further investigate the underlying mechanism by 
which Itln contributes to the pathogenesis of asthma. We found that Itln contributes to the 
expression of epithelial cytokines Il-25, Il-33, Tslp after OVA or HDM sensitization and 
challenge. Because Il-25, Il-33 and Tslp are key players in the innate immune response of 
epithelial cells exposed to allergens 41, our findings suggest Itln may play a role in the innate 
immune response. Pemberton and colleagues reported that Itln expression is increased early 
in enteric epithelial cells after nematode parasite infection and its expression peaks at of 
worm expulsion in resistant mouse strain 34. Voehringer and colleagues reported there was 
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substantial increase of Itln expression in Rag-deficient mice after parasite infection, 
suggesting the upregulation of Itln after parasite infection is independent of adaptive 
immunity 48. These findings prompted us to further investigate the role of in the allergen-
induced expression of epithelial proinflammatory cytokines.
To further investigate the role of Itln in the expression of IL-25, IL-33 and TSLP at the 
sensitization phase of asthma, we used a protocol in which mice are exposed to HDM 
intranasally for 3 consecutive days. This protocol induces sensitization without obvious 
airway inflammation 41. We found the expression of Il-25, Il-33 and Tslp were induced at 2–
6h after the last exposure to HDM. Itln1 expression was also induced early (at 2h) after the 
last exposure to HDM. However, HDM-induced Il-25, Il-33 and Tslp expression was 
suppressed in Itln KD mice. In in vitro experiments, HDM induced the expression of ITLN1, 
IL-25, IL-33 and TSLP in human bronchial epithelial cells at 2–6h. However, HDM-induced 
IL-25, IL-33, and TSLP expression was suppressed when ITLN1 expression was inhibited 
by RNA interference or when ITLN1 function was blocked by addition of galactose. Our 
findings provide evidence that ITLN may play a role in the innate immune response to 
airway allergen exposure by contributing to the expression of IL-25, IL-33 and TSLP. Our 
study has several limitations. First, we used negative littermates as wild type controls in 
mouse experiments. Mice overexpressing a scrambled shRNA would be a better control. 
Second, Itln knockdown did not completely block the expression of innate cytokines in 
mouse and in vitro experiments. This could be attributed to the incomplete suppression of 
Itln expression by RNA interference.
Since the EGFR and ERK pathway have been previously implicated in regulating IL-33 and 
TSLP expression in keratinocytes 42, 43, we examined the possibility that ITLN might 
participate in HDM-induced IL-25, IL-33 and TSLP expression via effects on EGFR and 
ERK activation. Consistent with this possibility, we found that EGFR and ERK 
phosphorylation was inhibited by ITLN1 RNA interference and that EGFR and ERK activity 
were required for HDM-induced IL-25, IL-33, and TSLP expression in BEAS-2B cells. 
Therefore, ITLN1 may participate in HDM-induced IL-25, IL-33, and TSLP expression, at 
least in part, through contributing to the activation of EGFR and ERK activation. The 
mechanism by which ITLN contributes to EGFR and ERK pathway activation is not yet 
known.
For the first time, we demonstrated that ITLN is highly expressed in the epidermis of 
lesional skin of subjects with atoptic dermatitis. Itln expression is also increased in 
epidermal keratinocytes of MC903 and HDM-induced atopic dermatitis models. The 
phenotypes of atopic dermatitis including ear swelling, reddening, epidermal hyperplasia 
and dermal infiltration of eosinophils were significantly reduced in Itln KD mice. Consistent 
with previous studies, we found that MC903 and HDM induced the expression of Il-4, Il-5, 
Il-13, Il-33, and Tslp in lesional skin 25, 45. We demonstrated that Itln contributed to the 
expression of these cytokines in these two different models of atopic dermatitis. These 
findings provide further evidence that Itln plays a critical role in innate immune response to 
allergen exposure by regulating the expression of innate cytokines.
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Consistent with our findings in mouse experiments, we demonstrated that ITLN1 expression 
is increased in airway epithelium of subjects with asthma and in lesional skin of subjects 
with atopic dermatitis. Epithelial ITLN1 transcript levels were correlated with the levels of 
eosinophils in induced sputum in subjects with asthma. Sputum and plasma ITLN1 protein 
levels were also markedly increased in subjects with asthma, and sputum ITLN1 protein 
levels were significantly correlated with sputum eosinophilia in subjects with asthma. This is 
consistent with a recent study reported that ITLN1 protein levels were increased in induced 
sputum of subjects with asthma during acute exacerbations and that ITLN1 levels were 
associated with eosinophila 38.
Taken together with previous reports, our data suggest a dual role for Itln in type 2 immune 
responses. As we show here, Itln contributes to initiating type 2 responses by regulating 
expression of Il-25, Il-33, and Tslp. Although knockdown of Itln reduced allergen-induced 
expression of these cytokines, previous studies showed that transgenic overexpression of Itln 
in type 2 pneumocytes did not induce type 2 responses 48, suggesting that the activity of 
ITLN depends upon other factors that are induced during innate immune responses. In 
addition to its role in initiation of type 2 responses, Itln also acts as an effector molecule that 
is induced as a consequence of type 2 immune responses. Itln/ITLN expression is increased 
rapidly in mouse lung and human bronchial epithelial cells after stimulation with IL-13, a 
type 2 cytokine 49, and helminth-induced Itln expression is dependent on the Il-13 and Il-4 
signaling molecule Stat6 48. Since Itln contributes to establishment of type 2 responses and 
is also produced as a consequence of these responses, Itln may contribute to the 
amplification of type 2 responses in asthma and AD.
METHODS
Subjects
We recruited 23 healthy control subjects and 48 subjects with asthma; most of these subjects 
(21 controls and 43 with asthma) were also included in a previous study 47. All subjects 
were Chinese and were recruited from Tongji Hospital. Subjects with asthma were 
diagnosed by a physician; had symptoms of episodic cough, wheeze and/or breathlessness; 
and had accumulated dosage of methacholine provoking a 20% fall of forced expiratory 
volume in the first second (FEV1 PD20) < 2.5mg and/or ≥12% increase in FEV1 following 
inhalation of 200μg salbutamol. Healthy control subjects had no respiratory symptoms, 
normal spirometric values and methacholine PD20 >2.5mg. None of the subjects had ever 
smoked or received inhaled or oral corticosteroid or leukotriene antagonist. For each subject, 
we recorded demographic information, collected blood and induced sputum samples, and 
performed spirometry and allergen skin prick testing with a panel of 14 aeroallergens. We 
performed bronchoscopy with brushing and endobronchial biopsies. We brushed 10 sites 
within the subsegmental bronchi of right middle and lower lobes (10 gentle upward and 
downward strokes per site). We used forceps to biopsy left lower lobe carinae and fixed 
samples in polyoxymethylene.
We collected skin biopsies from the lesional skin of 10 subjects with chronic AD and from 
the nonlesional skin of 8 control subjects who underwent hemangioma or adipoma surgery. 
AD patients were diagnosed according to the criteria described previously 50. Patients had 
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not received topical medication for at least 1 week or systemic medication for at least 4 
weeks before skin biopsies.
Generation of inducible transgenic shRNA (Itln knockdown) mice
We used C57BL/6 mice (Vital River, Beijing, China) to generate inducible transgenic 
shRNA mice because it has been reported that there is a natural deletion of Itln2 gene in the 
genomic DNA of C57BL/6 mice 34. The shRNA which was proven to suppress the 
expression of Itln1 in our previous study 40 was cloned into the pINV-7 vector (Taconic, 
Germany) to generate the inducible Itln shRNA transgenic construct (Supplemental Figure 
1A). The sequence of Itln1 shRNA (sense strand) was: 5′-
AAGGAAAGTGTTGGACTGACATTCAAGACGTGTCAGTCCAACACTTTC CTT-3′. 
pINV-7 vector is a bimodal DNA construct harboring an shRNA cassette under the control 
of a H1 promoter with a tetracycline operator (TetO) site and a cassette driving the 
expression of a codon-optimized tetracycline repressor (TetR) from the CAGGS 
promoter 51. The TetR binds to TetO and prohibits the expression of shRNA in absence of 
tetracycline or doxycycline, whereas the shRNA is expressed in presence of tetracycline or 
doxycycline. The Itln shRNA transgenic construct was used for pronuclear microinjection to 
generate five transgenic mouse lines. We checked for the functionality of the tetracycline-
inducible shRNA expression system by treating mice with 2 mg/mL doxycycline in the 
drinking water containing 50 mg/mL sucrose. We chose one transgenic line in which Itln1 
expression was mostly suppressed for all experiments. Eight- to 12-week-old mice were 
used in all experiments, and negative littermates were used as wild type controls. Both Itln 
knockdown mice and control mice were given doxycycline starting from 5 days before 
allergen sensitization.
Murine models of asthma
1) OVA-alum model. As described previously 52, 8 to 12-week-old female C57BL/6 mice 
(Vital River, Beijing, China) were sensitized by intraperitoneal administration of OVA (100 
μg in a total volume of 200 μl; Sigma-Aldrich, Grade V) mixed with 0.5 mg aluminum 
hydroxide three times at weekly intervals (day 0, 7, 14). Control mice received adjuvant 
alone. Beginning 1 week after the last injection, mice were challenged five times by 
intranasal administration of OVA (1000 μg in 50 μl saline) at daily intervals (day 21, 22, 23, 
24, 25). Control mice were challenged with saline alone. 2) HDM model. Mice were 
anesthetized with ether before intranasal aspiration of 40 μl of the solution of lyophilized 
HDM extract (2.5 mg/ml; Greer Laboratories) or saline on days 0, 1, 21, 22, and 23 53. 
Twenty-four hours after the last challenge of OVA or HDM, mice were anesthetized with 
tribromoethanol (400 mg/kg of body weight). We measured pulmonary resistance in 
response to a range of concentrations of intravenous acetylcholine using the forced 
oscillation technique with the FlexiVent system (SCIREQ) as previously described 54.
Murine model of allergen airway sensitization
Mice were anesthetized with ether before intranasal aspiration of 40 μl of the solution of 
lyophilized HDM extract (2.5 mg/ml; Greer Laboratories) or saline for 3 consecutive days. 
Mice were killed on 2, 6, and 24 hours after the last exposure.
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Murine models of atopic dermatitis
1) MC903 model. We resuspended calcipotriol (MC903; Sigma-Aldrich) in ethanol at 50 
μM and applied 1 nM (20 μl) daily to the outer and inner surfaces of the right for 9 days as 
described previously 45. We used ethanol as a vehicle control (20 μl/ear). Ear thickness was 
measured daily using vernier calipers. 2) HDM model. As previously 55, we applied 25 μl of 
the solution of lyophilized HDM extract (10 mg/ml; Greer Laboratories) to both surfaces of 
the right ear weekly for 5 weeks after the ear was stripped with tape. Ear thickness was 
measured before each MC903 or HDM application. Ear samples and serum were collected 
24 hours after the last application MC903 or HDM. Ear samples were fixed with formalin, 
embedded in paraffin, and stained with hematoxylin and eosin. Two investigators counted 
eosinophils blindly in 10 fields randomly defined in one representative ear section of each 
mouse.
Cell culture and treatment
BEAS-2B cells (CRL-9609, American Type Culture Collection) were cultured in DMEM/
high glucose (HyClone) in 6-well plates. When cells were 90% confluent, 4 μg hITLN1 
shRNA or scrambled shRNA plasmid in 250 μl of Opti-MEMI medium was mixed with 10 
μl lipofectamine 2000 (Invitrogen) diluted in 240 μl of medium and added to each well. Six 
hours later, the media were substituted with DMEM with or without HDM (25 μg/ml; Greer 
Lab). At the indicated time points, cells were harvested for quantitative RT-PCR and 
Western blotting, and the media were collected for ELISA. The sequence of ITLN1 shRNA 
(sense strand) was: 5′-
GCATCTTATTACTCACCCTATCTCGAGATAGGGTGAGTAATAAGATGC-3′. The 
sequence of scrambled shRNA (sense strand) was: 5′-
GCCCATTCTTATCATACTCATCTCGAGATGAGTATGATAAGAATGGGC-3′.
For inhibition of ITLN with galactose, galactose (Sigma) was added to the medium (final 
concentration 30 mM) 1 h before HDM stimulation. EGFR inhibitor PD153035 (Selleck, 
final concentration 5μM) and AG1478 (Selleck, final concentration 10μM), and MEK 
inhibitor U0126 (Selleck, final concentration 10μM) were added to the medium 1 h before 
HDM stimulation.
Quantitative RT-PCR
We isolated total RNA from bronchial epithelial brushings, mouse lungs and BEAS-2B cells 
using TRIzol (Invitrogen, USA) and synthesized first-strand cDNA using the PrimeScript 
RT reagent kit (Takara, Japan). The transcript levels of human ITLN1, IL-25, IL-33, TSLP 
in BEAS-2B cells and bronchial brushings, and mouse Itln1, Muc5ac, Il-4, Il-5, Il-13, Il-17a, 
Il-25, Il-33, Tslp in mouse lungs were determined by using the Takara Perfect Real Time 
PCR kit, Takara SYBR Premix ExTaq polymerase, and an ABI Prism 7500 PCR System. 
The primers used are listed in Supplemental Table 2. The cycle threshold (Ct) of each gene 
transcript was normalized to the mean Ct of β-actin and GAPDH. Fold differences were 
determined by the 2−ΔΔCt method 56.
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Western blotting
Mouse lungs and BEAS-2B cells were harvested at the indicated time points, twice with 
cold PBS, and lysed in RIPA lysis buffer (Goodbio technology, China) containing a protease 
inhibitor cocktail (Roche, Germany). After 30 min on ice, lysates were centrifuged at 
15,000×g for 5 min to remove insoluble material. 50 μg protein samples were resolved on 
10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred 
and immunoprobed with rabbit-anti-mouse Itln antibody (1:1000;Proteintech Group). 
Antibody was detected using horseradish peroxidase-conjugated anti-rabbit IgG (1:3000; 
Jackson ImmunoResearch Laboratories) followed by ECL Western blot detection reagent 
(Beyotime Biotech, China). Blots were stripped and then re-probed for β-actin (1:3000; 
Abcam, Cambridge, UK). Densitometry was performed using ImageJ (National Institutes of 
Health, USA) and the protein level of intelectin was indexed to beta-actin. For 
phosphorylated EGFR, total EGFR, phosphorylated ERK and total ERK Western blotting, 
rabbit monoclonal phospho-EGFR (Tyr1068) (1:1000), EGFR (1:1000), phospho-p44/42 
ERK1/2 (Thr202/Tyr204) (1:2000) and ERK1/2 antibody (1:1000) from Cell Signaling 
Technology were used.
Histology, immunohistochemistry, PAS staining
We stained 2 μm sections with hematoxylin and eosin (H&E) or rabbit-anti-human intelectin 
(94–145) antibody (1:400; Phoenix Pharmaceuticals, US) or an isotype matched control 
rabbit IgG (1:2000; Abmart Shanghai, China) for endobronchial and skin biopsies. For 
endobronchial biopsies, observers who were blinded to the clinical status of the subjects 
counted numbers of eosinophils/mm2 submucosa, and calculated basement membrane 
thickness (BMT). We used the mean of 50 measurements taken over a distance of at least 1 
mm to calculate BMT as previously described 57.
Mouse lungs were fixed for 5 min by instillation of 4% paraformaldehyde-PBS (Sigma, 
USA) through a tracheal catheter at a transpulmonary pressure of 15 cmH2O and lungs were 
fixed in 4% paraformaldehyde-PBS overnight. Five-μm-thick sections were used for 
immunohistochemistry with rabbit-anti-human intelectin (94–145) antibody (1:400; Phoenix 
Pharmaceuticals, USA) or an isotype matched control rabbit IgG (1:2000; Abmart Shanghai, 
China). Antibodies were detected using the DAB kit (Zhongshan Goldenbridge 
Biotechnology, China) as directed by the manufacturer. Lung sections were also stained with 
Periodic acid-Schiff (PAS; Goodbio technology, China) staining for detection of mucus. The 
number of PAS-staining-positive cells was counted in four random fields for each lung 
section at ×200 magnification 58.
Assessment of airway inflammation
Cell counts for macrophages, eosinophils, lymphocytes and neutrophils in bronchoalveolar 
lavage (BAL) fluid were performed as previously described 36. Paraffin-embedded 5-μm 
lung sections were stained with H&E. The severity of peribronchial inflammation was 
scored by a blinded observer using the following features: 0, normal; 1, few cells; 2, a ring 
of inflammatory cells 1 cell layer deep; 3, a ring of inflammatory cells 2–4 cells deep; 4, a 
ring of inflammatory cells of > 4 cells deep 59.
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Assessment of serum IgE levels
Blood was collected by cardiac puncture from antigen or vehicle-treated mice after airway 
responsiveness measurements in mouse models of allergic airway inflammation or 24 hours 
after the last challenge in mouse models of allergic skin inflammation. Serum IgE levels 
were measured by enzyme-linked immunosorbent assay (ELISA) with OVA-specific IgE 
(Cayman Chemical Company, USA) and total IgE (RayBiotech, USA).
ELISA
Mouse Il-4, Il-5, Il-13 in BALF and Il-25, Il-33, Tslp in mouse lung homogenate were 
determined using commercially available ELISA sets (R&D Systems, USA). ELISA was 
performed according to the manufacturer’s instructions. All samples and standards were 
measured in duplicate.
Flow cytometry
Mouse lung and mediastinal lymph nodes were isolated, minced, dispersed through nylon 
filters and washed. Cells were incubated for 4 hours at 37°C in RPMI containing PMA, 
ionomycin, and brefeldin A (Sigma-Aldrich, USA). Cells were then resuspended in PBS/2% 
FCS and stained with Cd4, Il-4 and Il-17A antibodies (Biolegend, China). Samples were 
analyzed on a FACSort flow cytometer (BD Biosciences, USA). Data were analyzed with 
FlowJo software (TreeStar, USA).
Statistics
We analyzed data using Prism version 5 (GraphPad Software, USA) and SPSS version 19 
(SPSS Inc., USA). For normally distributed data we calculated means ± standard deviation 
(SD) and used parametric tests (one-way analysis of variance with Tukey correction or 
unpaired t test) to compare across groups. For non-normally distributed data we calculated 
medians (with interquartile ranges) and used non-parametric tests (Kruskal-Wallis test with 
Dunn intergroup comparison or Mann-Whitney test). We analyzed correlation using 
Spearman’s rank order correlation.
Study Approval
All experiments were approved by the ethics committee of Tongji Hospital, Huazhong 
University of Science and Technology.
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Figure 1. 
Itln KD mice are protected from AHR, airway inflammation, mucus production and allergic 
response in the OVA asthma model. (a) Pulmonary resistance in response to different 
concentration of intravenous acetycholine in WT and Itln KD mice after sensitization and 
challenge with OVA or saline. n = 6–8 mice per group. (b) H&E staining of representative 
lung sections. Original magnification, ×200. (c) Inflammatory scores of lung sections were 
calculated as described in Materials and Methods. (d) Counts for macrophages, eosinophils, 
lymphocytes and neutrophils in BAL fluids. n = 6–8 mice per group. (e) Periodic acid-Schiff 
(PAS) staining for mucus in representative lung sections. Original magnification, ×200. (f) 
The numbers of PAS-staining-positive cells were counted in 4 random fields for each lung 
section at ×200 magnification. (g) Immunohistochemistry for Muc5ac in representative lung 
sections at ×200 magnification. (h) Muc5ac transcripts levels were determined by 
quantitative PCR. (i) Serum OVA-specific IgE in peripheral blood was determined by 
ELISA. n = 6–8 mice per group. Data are mean ± SEM. **, P < 0.01; ***, P < 0.001 vs. Itln 
KD mice challenged with OVA. Results are representative of 3 individual experiments.
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Figure 2. 
Itln contributes to the expression of Th2 cytokines and Il-25, Il-33, Tslp in the OVA asthma 
model. (a–c) The mRNA levels of Il-4, Il-5 and Il-13 in mouse lung were determined by 
quantitative PCR. (d–f) The protein levels of Il-4, Il-5 and Il-13 in mouse lungs were 
determined by ELISA. (g, h) Percentages of CD4+Il4+ cells in the lungs and mediastinal 
lymph nodes were determined by flow cytometry after intracellular staining. (i–k) The 
protein levels of Il-25, Il-33 and Tslp in mouse lung homogenates were determined by 
ELISA. n = 6–8 mice per group. Data are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 
0.001 vs. Itln KD mice challenged with OVA. Results are representative of 3 individual 
experiments.
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Figure 3. 
Itln contributes to HDM-induced Il-25, Il-33 and Tslp expression in mouse lungs. (a–d) The 
kinetics of Itln1, Il-25, Il-33 and Tslp expression in the lungs of WT mice after airway 
exposure to HDM were determined by quantitative PCR. n = 6 mice per group. Data are 
mean ± SEM. *, P < 0.05 vs. WT treated with vehicle. (e–h) The expression of Itln1, Il-25, 
Il-33 and Tslp in Itln KD mice and WT mice after airway exposure to HDM for 2h were 
determined by quantitative PCR. *, P < 0.05; **, P < 0.01; ***, P < 0.001 vs. WT mice 
exposed to HDM for 2h. Results are representative of 3 independent experiments.
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Figure 4. 
ITLN1 contributes to HDM-induced IL-25, IL-33 and TSLP expression and the activation of 
EGFR and ERK pathway in human bronchial epithelial cells. (a–d) The kinetics of ITLN1, 
IL-25, IL-33 and TSLP expression in BEAS-2B cells after exposure to HDM were 
determined by quantitative PCR. n = 4 wells per group. Data are mean ± SEM. **, P < 0.01; 
***, P < 0.001 vs. BEAS-2B cells treated with PBS. (e–h) The expression of ITLN1, IL-25, 
IL-33 and TSLP in BEAS-2B cells transfected with shRNA against ITLN1 or scrambled 
shRNA and exposed to HDM for 6h. n = 4 wells per group. Data are mean ± SEM. *, P < 
0.05; **, P < 0.01; ***, P < 0.001 vs. BEAS-2B cells treated with ITLN1 shRNA. (i) HDM 
stimulation increased EGFR and ERK phosphorylation, but ITLN1 shRNA transfection 
inhibited HDM-induced EGFR and ERK phosphorylation. Densitometry of phospho-EGFR 
relative to total EGFR (j), and phosphor-ERK relative to total ERK (k). Data are mean ± 
SEM from triplicates. ***, P < 0.001. The data are representative of 3 independent 
experiments.
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Figure 5. 
Itln KD mice are protected from allergic skin inflammation in MC903-induced AD model. 
(a) Ear thickness was measured daily before the daily application of MC903 or ethanol to 
the right ear. n = 5–8 mice per group. (b) The number of eosinophils in the ear was counted 
in 10 randomly selected views of one representative ear section from each mouse. (c) Serum 
total IgE level in peripheral blood was determined by ELISA. n = 5–8 mice per group. (d) 
Itln transcript levels in ear tissue were determined by quantitative PCR. n = 5–8 mice per 
group. (e) H&E staining, Masson trichrome staining and Itln immunohistochemistry of 
representative ear section. Original magnification, ×200. Data are mean ± SEM. **, P < 
0.01; ***, P < 0.001 vs. Itln KD mice after MC903 exposure. Results are representative of 3 
independent experiments.
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Figure 6. 
The expression of ITLN1 is increased in the airway and plasma of subjects with asthma, and 
is correlated with induced sputum eosinophils. (a) The transcript levels of ITLN1 in 
bronchial brushings of subjects with asthma (n = 48) and healthy controls (n = 32) were 
determined by quantitative PCR. Values were relative to median value of healthy controls 
and were log2 transformed. (b) Immunohistochemistry of ITLN1 in epithelium and 
submucosal gland in representative sections of bronchial biopsies from subjects with asthma 
and healthy controls. Original magnification, ×400. Correlation between ITLN1 transcript 
levels and (c) IL-25 transcript levels in bronchial brushings, and (d) the percentage of 
eosinophils in induced sputum of subjects with asthma (n = 48) and healthy control (n = 23). 
(e) Sputum ITLN1 protein levels of subjects with asthma (n = 24) and healthy controls (n = 
9) were determined by ELISA. (f) Correlation between sputum ITLN1 protein levels and the 
percentage of eosinophils in induced sputum of subjects with asthma (n = 24) and healthy 
control (n = 9). (g) Plasma ITLN1 protein levels of subjects with asthma (n = 48) and 
healthy controls (n = 32) were determined by ELISA.
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Figure 7. 
ITLN1 expression is increased in the epidermis of lesional skin of subjects with atopic 
dermatitis. (a) H&E staining and immunohistochemistry of ITLN1 in representative sections 
of normal skin of control subjects and in the lesional skin of subjects with atopic dermatitis. 
Original magnification, ×400. (b) Quantification of ITLN1 staining positive cells in the skin 
of control subjects (n = 8) and subjects with atopic dermatitis (n = 10) by counting ITLN1 
staining positive cells in the epidermis in 6–8 randomly selected views of each section.
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